In high grade glioma, Kiyatec 3D Predict™ accurately predicted therapeutic response rates in > 85% cases, providing physicians with patient-specific therapeutic response insights to inform their treatment planning for each patient.
KITATEC 3D PREDICT™ BROCHUREOur Science & Technology Provide Oncologists with Insights to Improve Clinical Outcomes
Our ex vivo 3D cell culture platforms enable us to utilize a patient's live cancer cells from surgical or biopsy tissue to create a patient-specific,
in vivo-like tumor and immune microenvironment, outside the body, to accurately model and assess response (ex vivo efficacy) to investigational and FDA-cleared cancer therapies.
Our unique ex vivo 3D cell culture approach maximizes patient relevance in the laboratory assessment of drug-on-tumor cell interaction prior to therapy administration, providing clinicians with patient-specific therapeutic response prediction in 7-10 business days, prior to initiation of therapy.
Kiyatec offers clinical testing for high-grade glioma and is developing tests for ovarian, breast, non-small cell lung and rare tumors in its CLIA-certified lab. Kiyatec works with leading biopharmaceutical companies to unlock response dynamics for investigational drug candidates for use in solid tumors.
ABOUT KIYATEC
Kiyatec is disrupting cancer care by providing oncologists with a functional precision assay that accurately predicts patient–specific therapeutic response and non–response before treatment begins.
Kiyatec is a leader in functional precision oncology. Kiyatec utilizes proprietary platforms across multiple solid tumor types, based on robust science that scores >95th percentile in peer reviewed journals.
